Clinical trial
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
NCT00401128 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00401128 |
|---|---|
| Title | Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer |
| Official title | Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, irinotecan hydrochloride |
| Enrollment | 9 |
| Start date | May 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Nov 17, 2006 |
| Last update posted | Apr 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: